SynthesisFrontiers in immunology2026
An integrated immunopathological model of syphilis serofast: a systematic review and meta-analysis.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The immunological mechanisms underlying the syphilis serofast remain incompletely elucidated. This systematic review and meta-analysis aims to quantify the association between key immune indicators and serofast. Methods: We systematically searched PubMed, Embase, Web of Science, Google Scholar and Chinese databases (CNKI, VIP, and CBMdisc) until December 31, 2024, for case-control, cross-sectional or cohort studies meeting serofast criteria (RPR/TRUST titer ≤1:8 persisting for ≥12 months). Random-effects models were used to calculate standardized mean differences (SMD) with 95% confidence intervals (CIs). The risk of bias was assessed using the Newcastle-Ottawa Scale (for observational studies) by two independent reviewers. Results: A total of 38 studies involving 5082 patients were included. The serofast group exhibited significant immune dysregulation: (1) Cellular immune suppression:decreased CD4+ T cells (SMD=-0.61, I²=33.5%) and increased CD8+ T cells (SMD = 0.40, I²=66.7%), leading to an inverted CD4+/CD8+ ratio (SMD=-0.44, I²=64.7%); (2) Th1/Th2 shift:suppression of Th1 cytokines (e.g., IFN-γ, SMD=-2.19, I²=95.7%) with a predominant Th2 response (e.g., IL-10, SMD =+ 2.63,I²=92.5%); (3) Humoral abnormalities: persistently elevated IgM (SMD = 0.96,I²=94.4%) and complement consumption (C3,SMD=-0.60, I²=89.0%; C4, SMD=-0.80, I²=87.6%); (4) Signaling dysregulation: downregulated TLR2 expression and disordered chemokine receptors (TLR2 mRNA,SMD=-1.52, I²=36.0%).The substantial heterogeneity (I² > 50%) observed in several analyses was explored in subgroup and sensitivity analyses, as detailed in the main text. Conclusions: The serofast is characterized by a cascade of "cellular immune suppression-Th1/Th2 shift-complement exhaustion." Our findings establish a quantified immunological basis for the serofast state and suggest potential targets for immunomodulatory therapy. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD420251156478.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.